Vitamin D insufficiency has been widely reported across diverse populations, including in sun-rich regions such as India. Serum 25-hydroxyvitamin D [25(OH)D] remains the most reliable biomarker for assessing vitamin D status. Over the past decade, the clinical interest surrounding vitamin D has expanded considerably, leading to increased test requisitions across healthcare settings. [1]
While heightened awareness of hypovitaminosis D is beneficial, indiscriminate laboratory testing may reduce diagnostic efficiency and impose cumulative financial strain on healthcare systems. Diagnostic stewardship emphasizes coordinated strategies to improve the appropriate use of laboratory investigations to enhance patient outcomes and resource optimization. [2]
In this context, the present study aimed to evaluate the requisition pattern of serum 25(OH)D testing in routine clinical practice and examine its implications from a diagnostic stewardship perspective in a tertiary teaching hospital.
Study Design and Setting
A hospital-based retrospective observational audit was conducted in the Department of Biochemistry at a tertiary teaching hospital in Maharashtra, India, from June 2021 to June 2023, following Institutional Ethics Committee approval.
A total of 287 subjects for whom serum 25(OH)D testing was requested from various outpatient and inpatient departments—including Medicine, Orthopaedics, Dermatology, Casualty, Obstetrics, and Surgery were included.
Serum 25(OH)D was measured using the ARCHITECT i1000SR Chemiluminescent Microparticle Immunoassay (CMIA). [3] The assay demonstrated intra- and inter-assay coefficients of variation below 5%. Laboratory-defined reference intervals were applied, with values <6.6 ng/mL and >49.9 ng/mL considered abnormal.
Data were expressed as mean ± standard deviation and percentages. The Kolmogorov–Smirnov test assessed normality. Chi-square and Fisher’s exact tests were applied where appropriate. Statistical significance was defined as p<0.05.
A total of 287 subjects for whom serum 25-hydroxyvitamin D [25(OH)D] testing was requisitioned during the study period were included in the analysis.
The general characteristics of the study subjects are shown in Table 1.
Table 1: General Characteristics of the Study Subjects
|
Sr.No. |
Parameters |
Value |
Mean ± Std. Deviation |
|
1. |
Gender n (%) Male Female |
136 (47.4%) 151 (52.6%) |
Age in years 28.526±27.0272 27.007±24.1322 |
|
|
Total subjects |
287 |
|
Table No. 2: Years Wise Distribution of Subjects
|
Year |
No. of patients (n=287) |
Percentage (%) |
|
2021 |
88 |
30.7 |
|
2022 |
158 |
55.1 |
|
2023 |
41 |
14.3 |
Table 3: Grading of 25-OH Vitamin D levels of subjects
|
Grading of 25-OH Vitamin D levels |
25-OH Vitamin D levels |
No of patients |
Percent% |
|
Low |
<6.6 (ng/ml) |
4 |
1.4% |
|
Normal |
6.6 – 49.9 (ng/ml) |
252 |
87.8% |
|
High |
>49.9 (ng/ml) |
31 |
10.8% |
|
Total subjects |
287 |
|
|
Table 4: Gender wise distribution of 25-OH Vitamin D levels of subjects
|
Gender |
Grading of 25-OH Vitamin D levels |
No of patients |
Percent% |
|
Male |
Low |
2 |
1.5% |
|
Normal |
120 |
88.2% |
|
|
High |
14 |
10.3% |
|
|
Female
|
Low |
2 |
1.3% |
|
Normal |
132 |
87.4% |
|
|
High |
17 |
11.3% |
Table 5. Department wise distribution of subjects with 25-OH Vitamin D levels
|
Department |
Grading of 25-OH Vitamin D levels |
No of subjects |
Percentage (%)
|
|
Casualty |
Low |
0 |
0 |
|
Normal |
18 |
90.0% |
|
|
High |
2 |
10.0% |
|
|
Dermatology |
Low |
1 |
5.0% |
|
Normal |
17 |
85.0% |
|
|
High |
2 |
10.0% |
|
|
Medicine |
Low |
1 |
0.7% |
|
Normal |
113 |
83.1% |
|
|
High |
22 |
16.2% |
|
|
Orthopaedics
|
Low |
2 |
1.8% |
|
Normal |
104 |
93.7% |
|
|
High |
5 |
4.5% |
The present retrospective audit evaluated serum 25-hydroxyvitamin D [25(OH)D] test utilization patterns across multiple clinical departments in a tertiary teaching hospital. The analysis demonstrated that the majority of results (87.8%) were within laboratory-defined reference intervals, while only a small proportion exhibited markedly low concentrations (1.4%). Notably, 10.8% of subjects had elevated levels, suggesting ongoing supplementation or increased clinician vigilance regarding vitamin D status.
Although vitamin D deficiency has been widely reported in Indian populations, the relatively low proportion of severely deficient values in this cohort warrants careful interpretation. [4] The laboratory-defined threshold for low vitamin D (<6.6 ng/mL) represents a stringent cut-off; broader clinical definitions often categorize deficiency at higher concentrations. Therefore, the observed distribution may reflect institutional reference standards rather than absence of subclinical insufficiency. Additionally, increasing public awareness, over-the-counter supplementation practices, and empiric vitamin D prescriptions may have influenced serum concentrations in the tested population. [5]
Department-wise analysis revealed variations in distribution patterns. Orthopaedics demonstrated a particularly high proportion of values within reference limits (93.7%), with relatively few elevated results (4.5%). This pattern likely reflects targeted testing in patients presenting with bone pain, osteoarthritis, fractures, or suspected metabolic bone disease, where deficiency is clinically anticipated but not universally present. In contrast, the Medicine department exhibited a comparatively higher proportion of elevated values (16.2%). This finding may be attributable to monitoring of patients already receiving supplementation, evaluation of chronic medical conditions, or broader screening practices in patients with nonspecific symptoms such as fatigue, myalgia, or generalized weakness.
Dermatology and Casualty services demonstrated similar predominance of values within reference limits. In dermatological practice, vitamin D testing is often considered in conditions such as psoriasis, vitiligo, alopecia, or chronic inflammatory dermatoses, given the proposed immunomodulatory role of vitamin D. In emergency settings, testing may be incidental or associated with musculoskeletal complaints. [6-8]
Gender-wise distribution showed a marginally higher proportion of females (52.6%) undergoing testing. While the difference was not striking, this observation is clinically plausible. Women are more frequently evaluated for osteoporosis, osteopenia, chronic musculoskeletal pain, and endocrine disturbances, all of which commonly prompt vitamin D assessment. Additionally, vitamin D testing may be performed during antenatal evaluation, in perimenopausal or postmenopausal women, and in those presenting with nonspecific symptoms such as fatigue or diffuse body ache. Sociocultural factors, including reduced sunlight exposure due to clothing practices and indoor lifestyle patterns, may also contribute to increased clinical suspicion in female patients. Conversely, in male patients, vitamin D testing is often considered in the context of metabolic syndrome, chronic liver disease, or musculoskeletal complaints, though routine screening is less commonly emphasized. [9,10]
The presence of elevated 25(OH)D levels in 10.8% of subjects deserves attention. While not necessarily indicative of toxicity, elevated concentrations may reflect unsupervised supplementation or prolonged empirical therapy without follow-up monitoring. This highlights the importance of balanced clinical judgment, ensuring that supplementation is evidence-based and periodically reassessed. [11,12]
From a laboratory utilization perspective, the predominance of results within reference intervals suggests that vitamin D testing is frequently incorporated into routine clinical evaluation across specialties. Such patterns are not inherently inappropriate; rather, they reflect evolving perceptions of vitamin D as a systemic biomarker. However, periodic audit of requisition patterns remains valuable to ensure alignment between clinical indication and diagnostic yield. [13]
The present study has certain limitations. Its retrospective design precludes detailed correlation with clinical indications, supplementation history, and therapeutic outcomes. Furthermore, institution-specific reference intervals may differ from broader guideline-based thresholds, influencing classification of deficiency and sufficiency.
In conclusion, this audit provides insight into real-world vitamin D testing practices within a tertiary care setting. The findings underscore the importance of contextual interpretation of laboratory data, recognition of specialty-specific requisition patterns, and continued evaluation of diagnostic utility to support rational and value-based healthcare delivery.
B.K.L.Walawalkar Rural Medical College, Sawarde-415606, Dist.Ratnagiri (Maharashtra)
None
None
[1] Kalra S, Zargar AH, Das AK, Baidya A, Dasgupta A, Selvan C, Bantwal G, Kapoor N, Lakhani OJ, Agarwal PK, Bajaj S, Sarathi V; Vitamin D Consensus Steering Committee. Prevention and Treatment of Vitamin D Deficiency in India: An Expert Group Consensus. Indian J Endocrinol Metab. 2025 Jan-Feb;29(1):13-26. doi: 10.4103/ijem.ijem_264_24. Epub 2025 Feb 28. PMID: 40181864; PMCID: PMC11964374.
[2] Má?ová L, Bi?íková M. Vitamin D: Current Challenges between the Laboratory and Clinical Practice. Nutrients. 2021 May 21;13(6):1758. doi: 10.3390/nu13061758. PMID: 34064098; PMCID: PMC8224373.
[3] Cinquanta L, Fontana DE, Bizzaro N. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? Auto Immun Highlights. 2017 Dec;8(1):9. doi: 10.1007/s13317-017-0097-2. Epub 2017 Jun 24. PMID: 28647912; PMCID: PMC5483212.
[4] G R, Gupta A. Vitamin D deficiency in India: prevalence, causalities and interventions. Nutrients. 2014 Feb 21;6(2):729-75. doi: 10.3390/nu6020729. PMID: 24566435; PMCID: PMC3942730.
[5] Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc. 2010 Aug;85(8):752-7; quiz 757-8. doi: 10.4065/mcp.2010.0138. PMID: 20675513; PMCID: PMC2912737.
[6] Barrea L, Savanelli MC, Di Somma C, Napolitano M, Megna M, Colao A, Savastano S. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev Endocr Metab Disord. 2017 Jun;18(2):195-205. doi: 10.1007/s11154-017-9411-6. PMID: 28176237; PMCID: PMC5486909.
[7] Lugovi?-Mihi? L, Toluši?Levak M, Špi?i? S, Bulat V, Brki? A, Šešerko A. VITAMIN D IN PATIENTS WITH INFLAMMATORY SKIN DISEASES. Acta Clin Croat. 2025 Mar;64(1):118-128. doi: 10.20471/acc.2025.64.01.13. PMID: 41340803; PMCID: PMC12671712.
[8] Mostafa WZ, Hegazy RA. Vitamin D and the skin: Focus on a complex relationship: A review. J Adv Res. 2015 Nov;6(6):793-804. doi: 10.1016/j.jare.2014.01.011. Epub 2014 Feb 8. PMID: 26644915; PMCID: PMC4642156.
[9] Alswat KA. Gender Disparities in Osteoporosis. J Clin Med Res. 2017 May;9(5):382-387. doi: 10.14740/jocmr2970w. Epub 2017 Apr 1. PMID: 28392857; PMCID: PMC5380170.
[10] De Martinis M, Sirufo MM, Polsinelli M, Placidi G, Di Silvestre D, Ginaldi L. Gender Differences in Osteoporosis: A Single-Center Observational Study. World J Mens Health. 2021 Oct;39(4):750-759. doi: 10.5534/wjmh.200099. Epub 2020 Nov 26. PMID: 33474849; PMCID: PMC8443988.
[11] Taylor PN, Davies JS. A review of the growing risk of vitamin D toxicity from inappropriate practice. Br J Clin Pharmacol. 2018 Jun;84(6):1121-1127. doi: 10.1111/bcp.13573. Epub 2018 Apr 16. PMID: 29498758; PMCID: PMC5980613.
[12] Choi R, Chun G, Cho SE, Ahn S, Lee SG, Lee EH. Increasing Prevalence of Potential Vitamin D Toxicity and Its Risk Factors in Korea: A Large Population-Based Study. Nutrients. 2025 Aug 12;17(16):2614. doi: 10.3390/nu17162614. PMID: 40871642; PMCID: PMC12389275.
[13] Má?ová L, Bi?íková M. Vitamin D: Current Challenges between the Laboratory and Clinical Practice. Nutrients. 2021 May 21;13(6):1758. doi: 10.3390/nu13061758. PMID: 34064098; PMCID: PMC8224373.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications